We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+73.06%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$912M
AUM Growth
-$156M
Cap. Flow
-$257M
Cap. Flow %
-28.19%
Top 10 Hldgs %
35.78%
Holding
190
New
54
Increased
34
Reduced
35
Closed
53

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.96M
2
CYTK icon
Cytokinetics
CYTK
+$8.91M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.6M
4
JBIO
Jade Biosciences
JBIO
+$8.03M
5
PYXS icon
Pyxis Oncology
PYXS
+$6.99M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$26.5M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$21.4M
3
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$19.1M
4
NUVL
Nuvalent
NUVL
+$12.5M
5
IRON icon
Disc Medicine
IRON
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 39.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
101
ProQR Therapeutics
PRQR
$243M
$1.1M 0.12%
483,583
+10,958
+2% +$23.4K
IFRX icon
102
InflaRx
IFRX
$250M
$1.09M 0.12%
704,987
+16,383
+2% +$26.8K
ABOS icon
103
Acumen Pharmaceuticals
ABOS
$155M
$1.08M 0.12%
266,435
-48,830
-15% -$184K
ROIV icon
104
Roivant Sciences
ROIV
$24.5B
$1.06M 0.12%
100,609
-51,212
-34% -$552K
AVTX icon
105
Avalo Therapeutics
AVTX
$965M
$1.01M 0.11%
+46,648
New +$251K
TECX
106
Tectonic Therapeutic
TECX
$529M
$965K 0.11%
62,838
+2,983
+5% +$47.2K
AMLX icon
107
Amylyx Pharmaceuticals
AMLX
$2.26B
$941K 0.1%
331,451
-546,049
-62% -$7.14M
MIST icon
108
Milestone Pharmaceuticals
MIST
$138M
$834K 0.09%
466,019
+3,191
+0.7% +$5.18K
TARA icon
109
Protara Therapeutics
TARA
$220M
$813K 0.09%
202,701
+14,037
+7% +$45.3K
KZR
110
DELISTED
Kezar Life Sciences
KZR
$783K 0.09%
86,899
+1,560
+2% +$14.2K
RAPT
111
CALL
DELISTED
RAPT Therapeutics
RAPT
$783K 0.09%
+10,900
New +$1.52M
ELEV
112
DELISTED
Elevation Oncology
ELEV
$760K 0.08%
148,089
-1,023,850
-87% -$3.32M
NYXH
113
Nyxoah
NYXH
$140M
$684K 0.08%
+50,699
New +$579K
VERU icon
114
Veru
VERU
$36M
$663K 0.07%
+94,638
New +$504K
KPTI icon
115
Karyopharm Therapeutics
KPTI
$43.5M
$618K 0.07%
27,290
+623
+2% +$10.9K
TERN
116
DELISTED
Terns Pharmaceuticals
TERN
$581K 0.06%
88,497
-76,983
-47% -$503K
AMLX icon
117
PUT
Amylyx Pharmaceuticals
AMLX
$2.26B
$529K 0.06%
+186,400
New +$2.44M
IMTX icon
118
Immatics
IMTX
$1.18B
$519K 0.06%
49,415
+384
+0.8% +$4.48K
CBIO
119
CALL
Crescent Biopharma
CBIO
$537M
$518K 0.06%
+1,728
New +$516K
CBIO
120
PUT
Crescent Biopharma
CBIO
$537M
$518K 0.06%
+1,728
New +$516K
ABEO icon
121
CALL
Abeona Therapeutics
ABEO
$366M
$489K 0.05%
+67,500
New +$428K
ANEB
122
DELISTED
Anebulo Pharmaceuticals
ANEB
$453K 0.05%
157,862
– –
TPST icon
123
Tempest Therapeutics
TPST
$13.7M
$413K 0.05%
8,123
– –
CRNX icon
124
CALL
Crinetics Pharmaceuticals
CRNX
$8.84B
$407K 0.04%
8,700
-91,300
-91% -$3.57M
QTTB icon
125
Q32 Bio
QTTB
$466M
$381K 0.04%
+22,335
New +$308K
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Ikarian Capital held 190 positions worth $912M, down 15% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Ikarian Capital withdrew a net $257M in Q1 2024, closing 53 positions and reducing 35 holdings. Its most notable exit was argenx, an estimated $26.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 32% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Alnylam Pharmaceuticals worth $7.7M.

  • Ikarian Capital's largest Q1 2024 buy was Alnylam Pharmaceuticals: 51,541 shares worth $7.7M.
  • Ikarian Capital added most to Corbus Pharmaceuticals in Q1 2024, an estimated $8.96M increase.
  • Ikarian Capital's biggest Q1 2024 reduction was Longboard Pharmaceuticals, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited argenx in Q1 2024, selling an estimated $26.5M.
  • Ikarian Capital's ten largest holdings make up 36% of its $912M portfolio in Q1 2024.
  • Ikarian Capital opened 54 new positions and closed 53 in Q1 2024.
  • Ikarian Capital's portfolio value fell 15% quarter-over-quarter to $912M.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.